PURPOSE: NS398, a selective COX-2 inhibitor, is known to inhibit the growth of COX-2 expressing hepatocellular carcinoma cells. The present study investigated whether the cytotoxic effect of NS398 was COX-2 dependent and whether caspases were involved in NS398-induced apoptosis in hepatocellular carcinoma cells. MATERIALS AND METHODS: The expressions of COX-2 in SNU 423 and SNU 449 hepatocellular carcinoma cell lines were examined using RT-PCR and Western blot. The cytotoxic effect of NS398 was measured using MTT in the presence or absence of caspase inhibitors. The distribution of the cell cycle and extent of apoptosis were analyzed using flow cytometry and a Cell Death Elisa kit, respectively. RESULTS: The expression of COX-2 was observed in SNU423 cells, but not in SNU 449 cells. NS398 treatment resulted in both dose-and time-dependent growth inhibitions, with increases in apoptotic cells in both cell lines. Treatment with the pan-caspase inhibitor, z-VAD- fmk, or the caspase-3 inhibitor, Ac-DMQD-CHO, showed no attenuation of the cytotoxic effect of NS398 in either cell line. CONCLUSION: This study demonstrated that the cytotoxic effect of NS398 was independent of COX-2 expression. Caspases were also shown not to be involved in NS398-induced apoptosis in either SNU 423 or SNU 449 Korean HCC cell lines. Our data suggests the feasibility of preventing hepatocellular carcinoma with the use of COX-2 inhibitors needs to be carefully evaluated.
PURPOSE:NS398, a selective COX-2 inhibitor, is known to inhibit the growth of COX-2 expressing hepatocellular carcinoma cells. The present study investigated whether the cytotoxic effect of NS398 was COX-2 dependent and whether caspases were involved in NS398-induced apoptosis in hepatocellular carcinoma cells. MATERIALS AND METHODS: The expressions of COX-2 in SNU 423 and SNU 449 hepatocellular carcinoma cell lines were examined using RT-PCR and Western blot. The cytotoxic effect of NS398 was measured using MTT in the presence or absence of caspase inhibitors. The distribution of the cell cycle and extent of apoptosis were analyzed using flow cytometry and a Cell Death Elisa kit, respectively. RESULTS: The expression of COX-2 was observed in SNU423 cells, but not in SNU 449 cells. NS398 treatment resulted in both dose-and time-dependent growth inhibitions, with increases in apoptotic cells in both cell lines. Treatment with the pan-caspase inhibitor, z-VAD- fmk, or the caspase-3 inhibitor, Ac-DMQD-CHO, showed no attenuation of the cytotoxic effect of NS398 in either cell line. CONCLUSION: This study demonstrated that the cytotoxic effect of NS398 was independent of COX-2 expression. Caspases were also shown not to be involved in NS398-induced apoptosis in either SNU 423 or SNU 449 Korean HCC cell lines. Our data suggests the feasibility of preventing hepatocellular carcinoma with the use of COX-2 inhibitors needs to be carefully evaluated.
Authors: Alfred S L Cheng; Henry L Y Chan; Wai K Leung; Nathalie Wong; Philip J Johnson; Joseph J Y Sung Journal: Int J Oncol Date: 2003-07 Impact factor: 5.650
Authors: H Koga; S Sakisaka; M Ohishi; T Kawaguchi; E Taniguchi; K Sasatomi; M Harada; T Kusaba; M Tanaka; R Kimura; Y Nakashima; O Nakashima; M Kojiro; T Kurohiji; M Sata Journal: Hepatology Date: 1999-03 Impact factor: 17.425
Authors: Michael André Kern; Dominic Schubert; Dina Sahi; Mirja Mareike Schöneweiss; Ilona Moll; Anke Maria Haugg; Hans Peter Dienes; Kai Breuhahn; Peter Schirmacher Journal: Hepatology Date: 2002-10 Impact factor: 17.425
Authors: Young Kwan Sung; Sun Young Hwang; Jin Oh Kim; Han Ik Bae; Jung-Chul Kim; Moon Kyu Kim Journal: Mol Cells Date: 2004-02-29 Impact factor: 5.034
Authors: Mi Kyung Park; Sun Young Hwang; Jin Oh Kim; Mi Hee Kwack; Jung-Chul Kim; Moon Kyu Kim; Young Kwan Sung Journal: Mol Cells Date: 2004-02-29 Impact factor: 5.034
Authors: Mohammad Farooq; Sun Young Hwang; Mi Kyung Park; Jung-Chul Kim; Moon Kyu Kim; Young Kwan Sung Journal: Mol Cells Date: 2003-06-30 Impact factor: 5.034
Authors: Sanjeewani T Palayoor; Molykutty J-Aryankalayil; Adeola Y Makinde; David Cerna; Michael T Falduto; Scott R Magnuson; C Norman Coleman Journal: J Cardiovasc Pharmacol Date: 2012-06 Impact factor: 3.105